Tags

Type your tag names separated by a space and hit enter

Measles seroepidemiology among adolescents and young adults: response to revaccination.
East Mediterr Health J. 2006 Sep; 12(5):573-81.EM

Abstract

We evaluated the seroprevalence of measles antibody and response to measles reimmunization in 590 previously vaccinated adolescents and young adults; 263 were seronegative. To differentiate between primary and secondary vaccine failure, anti-measles IgM and IgG titres were assessed again 2-4 weeks after revaccination in 144 (105 seronegative, 39 seropositive) individuals: 75 seronegative participants responded to revaccination anamnestically (P < 0.001) and developed immunity, 11 also showed IgM response (probably primary vaccine failure); 38 seropositive participants remained seroprotected without significant increase in antibody titre (P = 0.577). Primary vaccine failure was 4.7%; secondary vaccine failure was 27.1%. After revaccination, 87.3% were seroprotected.

Links

FREE Publisher Full Text

Authors+Show Affiliations

Saffar MJ
Department of Paediatrics, Paediatric Infectious Disease Ward, Bouali-Cina Hospital, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran. saffar@softhome.net
Alraza-Amiri M
No affiliation info available
Ajami A
No affiliation info available
Baba-Mahmoodi F
No affiliation info available
Khalilian AR
No affiliation info available
Vahidshahi C
No affiliation info available
Shamsizadeh A
No affiliation info available

MeSH

AdolescentAdultAftercareAntibodies, ViralEnzyme-Linked Immunosorbent AssayFemaleHealth Services Needs and DemandHumansImmunization ScheduleImmunization, SecondaryImmunoglobulin GImmunoglobulin MIranMaleMass ScreeningMass VaccinationMeaslesMeasles VaccineMeasles virusPopulation SurveillanceSeroepidemiologic StudiesTreatment Failure

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17333796

Citation

Saffar, M J., et al. "Measles Seroepidemiology Among Adolescents and Young Adults: Response to Revaccination." Eastern Mediterranean Health Journal = La Revue De Sante De La Mediterranee Orientale = al-Majallah Al-sihhiyah Li-sharq Al-mutawassit, vol. 12, no. 5, 2006, pp. 573-81.
Saffar MJ, Alraza-Amiri M, Ajami A, et al. Measles seroepidemiology among adolescents and young adults: response to revaccination. East Mediterr Health J. 2006;12(5):573-81.
Saffar, M. J., Alraza-Amiri, M., Ajami, A., Baba-Mahmoodi, F., Khalilian, A. R., Vahidshahi, C., & Shamsizadeh, A. (2006). Measles seroepidemiology among adolescents and young adults: response to revaccination. Eastern Mediterranean Health Journal = La Revue De Sante De La Mediterranee Orientale = al-Majallah Al-sihhiyah Li-sharq Al-mutawassit, 12(5), 573-81.
Saffar MJ, et al. Measles Seroepidemiology Among Adolescents and Young Adults: Response to Revaccination. East Mediterr Health J. 2006;12(5):573-81. PubMed PMID: 17333796.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Measles seroepidemiology among adolescents and young adults: response to revaccination. AU - Saffar,M J, AU - Alraza-Amiri,M, AU - Ajami,A, AU - Baba-Mahmoodi,F, AU - Khalilian,A R, AU - Vahidshahi,C, AU - Shamsizadeh,A, PY - 2007/3/6/pubmed PY - 2007/4/7/medline PY - 2007/3/6/entrez SP - 573 EP - 81 JF - Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit JO - East Mediterr Health J VL - 12 IS - 5 N2 - We evaluated the seroprevalence of measles antibody and response to measles reimmunization in 590 previously vaccinated adolescents and young adults; 263 were seronegative. To differentiate between primary and secondary vaccine failure, anti-measles IgM and IgG titres were assessed again 2-4 weeks after revaccination in 144 (105 seronegative, 39 seropositive) individuals: 75 seronegative participants responded to revaccination anamnestically (P < 0.001) and developed immunity, 11 also showed IgM response (probably primary vaccine failure); 38 seropositive participants remained seroprotected without significant increase in antibody titre (P = 0.577). Primary vaccine failure was 4.7%; secondary vaccine failure was 27.1%. After revaccination, 87.3% were seroprotected. SN - 1020-3397 UR - https://www.unboundmedicine.com/medline/citation/17333796/Measles_seroepidemiology_among_adolescents_and_young_adults:_response_to_revaccination_ L2 - http://applications.emro.who.int/emhj/1205/12_5_2006_573_581.pdf DB - PRIME DP - Unbound Medicine ER -